Background: In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety, but no significant clinical benefit was detected. Objective: We sought to investigate mechanisms by which omalizumab modulates immunity in the context of OIT and to identify baseline biomarkers that predict subgroups of patients most likely to benefit from omalizumab. Methods: Blood was obtained at baseline and multiple time points during a placebo-controlled trial of OIT for milk allergy in which subjects were randomized to receive omalizumab or placebo. Immunologic outcomes included measurement of basophil CD63 expression and histamine release and caseinspecific CD4
Food allergy affects approximately 15 million Americans and is the most common cause of anaphylaxis outside the hospital setting. 1 No US Food and Drug Administration-approved treatment for food allergy is currently available. Recent studies suggest that oral immunotherapy (OIT), in which allergenic food is SU: Sustained unresponsiveness Treg: Regulatory T mixed into a vehicle and then ingested in gradually increasing quantities, might hold promise as a treatment for food allergy. 2, 3 However, enthusiasm for this therapy has been tempered by the frequent occurrence of adverse reactions and the lack of sustained protection in most subjects once treatment is discontinued. 2, 3 These limitations have sparked investigations into adjunctive therapies, including omalizumab, that could improve both safety and long-term efficacy. Omalizumab is a humanized mAb that sequesters free IgE and prevents its binding to the high-affinity IgE receptor FcεRI. Recently, we completed the first double-blind, placebo-controlled trial of omalizumab in combination with OIT in patients with severe persistent cow's milk allergy. 4 Although no statistically significant benefit of omalizumab in promoting desensitization was detected compared with subjects receiving milk oral immunotherapy (MOIT) alone, omalizumab-treated subjects exhibited highly significant improvements in nearly all safety parameters. 4 Similar to other immunotherapy trials for food allergy, we observed significant heterogeneity in the frequency and severity of adverse reactions, as well as clinical responses both within and between treatment groups. 4 Identification of biomarkers that could predict which subjects are at highest risk of reactions and which are most likely to benefit from adjunctive therapies would have tremendous value in efforts to translate these therapies into clinical practice. To accomplish this goal, a greater understanding of the immunologic mechanisms underlying successful treatment is needed, as well as how adjunctive therapies, such as omalizumab, can facilitate these effects. Suppression of mast cell and basophil reactivity, increase in food-specific IgG 4 levels, decrease in food-specific IgE levels, and reduction in T H 2 immune responses are mechanisms most often associated with successful immunotherapy to food allergens. 5, 6 By preventing the interaction between circulating IgE and FcεRI, omalizumab suppresses expression of FcεRI on the surfaces of basophils, mast cells, and antigen-presenting cells, leading to reduced allergen-mediated activation of these cells. [7] [8] [9] However, some clinical studies have demonstrated that basophils from a subset of patients treated with omalizumab exhibited no change or, paradoxically, greater responsiveness to IgE receptor cross-linking after treatment. [10] [11] [12] These subjects experienced less clinical benefit from omalizumab, particularly if they had higher baseline allergen-specific/ total IgE ratios. 12 In this study we sought to dissect the effects of omalizumab on basophil and T-cell allergen-induced activation in subjects undergoing MOIT and to explore whether baseline biomarkers can predict which subjects are likely to benefit the most from adjunctive treatment with omalizumab.
METHODS

Clinical study
Participants aged 7 to 35 years were enrolled in a randomized, multicenter, double-blind, placebo-controlled trial of MOIT combined with omalizumab in the treatment of challenge-confirmed IgE-mediated cow's milk allergy. The study design and clinical outcomes have been reported previously. 4 Briefly, 57 subjects were randomized 1:1 to receive either omalizumab (n 5 28) or placebo (n 5 29) injections. One subject dropped out of each arm before starting injections. Omalizumab-treated subjects whose dose fell outside the package insert dosing chart received 0.016 mg/kg/IgE IU; subjects whose calculated dose was greater than 750 mg were excluded. At month 4, all subjects began MOIT dosing and were built up to a minimum maintenance dose of 520 mg of milk protein. Subjects continued blinded omalizumab or placebo injections through month 16. At month 16, all subjects were unblinded, and placebotreated subjects discontinued placebo dosing, whereas omalizumab-treated subjects continued active injections until month 28. All randomized subjects completed a 10-g desensitization oral food challenge (OFC) at month 28 (n 5 26 in the omalizumab arm and n 5 24 in the placebo arm at month 28 because of 1 additional withdrawal in the omalizumab arm and 4 in the placebo arm). Subjects in whom this OFC failed discontinued MOIT (n 5 2 in the omalizumab group and n 5 4 in the placebo group), whereas those who had passing OIT results continued MOIT dosing until month 30, at which point they discontinued and underwent a 10-g tolerance OFC at month 32. Participants who passed the month 32 challenge were considered to have achieved sustained unresponsiveness (SU), which was defined as lack of reactivity after milk ingestion after 8 weeks of milk avoidance (n 5 13 in the omalizumab group and n 5 10 in the placebo group). Blood was collected at baseline and at each of the time points described above, as well as at month 22. The clinical study was approved by the institutional review boards of the Icahn School of Medicine at Mount Sinai, Johns Hopkins University, and Stanford University, and informed consent/assent was obtained from all participants.
Basophil assays
Whole heparinized blood or washed basophil-enriched suspensions were prepared, as previously described, and stimulated with milk allergen, anti-IgE, or media alone and assayed for basophil CD63 expression or histamine release (HR), respectively. 13, 14 Additional details are provided in the Methods section in this article's Online Repository at www.jacionline.org.
Casein-specific regulatory T-cell assay
1 ) proliferation was assessed by means of dilution of carboxyfluorescein diacetate succinimidyl ester-labeled PBMCs, as described in the Methods section in this article's Online Repository.
Immunoglobulin measurements
Quantification of milk-specific, casein-specific, b-lactoglobulin-specific, and total IgE and IgG 4 was done by using the ImmunoCAP assay (Thermo Fisher Scientific, Waltham, Mass).
Statistical analysis
Wilcoxon rank sum tests, analysis of covariance, and paired t tests were used to analyze continuous variables, logistic regression and Fisher exact tests were used to analyze categorical data, and Spearman correlations were used to assess associations. We analyzed all randomized subjects, and those without OFC outcome data were considered failures.
To identify subgroups in which omalizumab might be most beneficial, we first identified promising prognostic variables from graphic displays. We then applied the approach of Shuster and van Eys, 15 fitting regression models that allowed the omalizumab effect to vary as a function of these prognostic factors and to construct regions with the strongest evidence of omalizumab advantage by using logistic regression for binary and ordinal outcomes and linear regression for continuous outcomes. Given the exploratory nature of this analysis, these resulting subgroups should be viewed as preliminary.
We describe results with 2-sided P values of less than .05 as statistically significant, but results should be viewed cautiously because of the multiplicity of analyses. However, given that many of these variables are very highly correlated, concerns about multiplicity are considerably less than if these were independent variables. See the Methods section in this article's Online Repository for additional details.
RESULTS
Basophil CD63 expression
Upregulation of CD63 is frequently used as a measure of basophil responsiveness. 16, 17 Basophils from omalizumab-treated subjects showed decreased milk-induced CD63 expression relative to baseline values at month 4 after starting omalizumab but before initiating MOIT (P 5 .0074 and .0135 at 0.1 and 10 mg/ mL milk, respectively; Fig 1) . This suppression was not evident in the placebo group at month 4 (Fig 1) . After adjusting for baseline values, CD63 percentages were lower in omalizumab-treated subjects compared with those in placebo-treated subjects at month 4 (P 5.0040, .0510, and .0014 for milk stimulant concentrations of 0.1, 1, and 10 mg/mL, respectively). After the visit at month 4, when both arms initiated MOIT, CD63 percentages after milk stimulation decreased in both groups compared with baseline values and remained significantly suppressed through month 28. As previously reported, in a longitudinal analysis CD63 expression was significantly decreased in the omalizumab arm relative to the placebo arm through month 28 at the 3 highest concentrations of milk (Fig 1) . 4 We also observed significant decreases in CD63 expression at month 28 from baseline at a P value of less than .01 at all concentrations of milk for both arms, except for the placebo group at 10 mg/mL. 4 Despite continued maintenance dosing at month 30, milkinduced CD63 expression increased in both groups such that the CD63 percentage was no longer significantly suppressed compared with baseline values in either omalizumab-or placebo-treated subjects at 1 or 10 mg/mL milk (Fig 1) . CD63 expression was also not lower than baseline values at month 32 after MOIT had been discontinued for 8 weeks (Fig 1) .
Basophil CD63 expression after anti-IgE stimulation did not change over the course of the study in the placebo group (Fig 1) . However, CD63 expression to anti-IgE increased steadily in the omalizumab-treated subjects, reaching a highly significant increase from baseline at month 30 (P 5 .0043) and month 32 (P 5 .0003, Fig 1) .
Basophil histamine release
To determine how serum factors might be influencing basophil responses during the course of the study, we prepared washed basophil-enriched suspensions from a subset of subjects, stimulated them under conditions identical to those for whole blood samples, and measured HR, which correlates closely with CD63 expression. 13 Although our sample size was small (n 5 7 for the omalizumab group and n 5 10 for the placebo group), HR to each of the 5 concentrations of milk was higher at nearly all visits compared with baseline values in omalizumab-treated subjects (P 5 .0240 at month 16 at 0.001 mg/mL and P 5 .0199, .0302, and .0294 at the month 16, 22, and 28 visits, respectively, at 1 mg/mL; Fig 2) . This pattern was less evident in the placebo group. Furthermore, in omalizumab-treated subjects only, HR to anti-IgE increased dramatically at month 4 (P 5 .0035) and These data were previously presented in Chinthrajah et al. 5 remained higher compared with baseline values (P < .0005 at months 16, 20, and 28) until omalizumab therapy was discontinued at month 28 (Fig 2) .
Subjects receiving omalizumab exhibited a decrease in spontaneous HR at month 4, although this did not reach statistical significance. This change was not evident in the placebo group (Fig 2) . Subjects in both arms experienced significant decreases in spontaneous HR after addition of MOIT (omalizumab group: P 5.0101 at month 20 and P 5.0274 at month 28; placebo group: P 5 .0336 at month 16 and P 5 .0182 at month 28; Fig 2) , but levels returned to baseline by month 30.
Frequency of milk-specific Treg cells
Neither omalizumab-treated (n 5 13) nor placebo-treated (n 5 11) subjects exhibited a significant increase in the percentage of casein-specific Treg cells over the course of treatment (see Fig 
Relationship between symptoms and clinical outcome
To determine the relationship between the frequency of symptoms that subjects experienced during MOIT and the degree of desensitization they achieved, we evaluated clinical responses as an ordinal variable, where SU (passed month 32 OFC) is the best outcome, desensitization (passed month 28 OFC but failed month 32 OFC) is the intermediate outcome, and failure (failed month 28 OFC) is the worst outcome. Clinical responses were highly associated with symptoms during treatment, such that the lower the rate of symptoms, the greater the likelihood of better clinical outcome (Fig 3) . This was highly statistically significant in the overall population for the 3 symptom categories during the entire study (P 5 .0057 for moderate-to-severe symptoms, P 5 .0038 for gastrointestinal symptoms, and P 5 .0013 for any symptom, excluding oropharyngeal symptoms). Results were also generally significant for the escalation and maintenance phases separately (Fig 3) . These relationships were generally stronger in the placebo arm compared with the omalizumab arm when the groups were analyzed separately (Fig 3) .
Relationship between baseline biomarkers and symptoms
As shown in Fig 4 , subjects whose basophils showed greater reactivity (percentage CD63 positive) to milk at baseline generally exhibited higher rates of adverse reactions, suggesting that these subjects might have the greatest potential for improved safety with omalizumab. A regression model that allowed the effect of omalizumab to vary with baseline CD63 percentage at 10 mg/mL milk determined a significant advantage from omalizumab, starting at values of 34% for moderate-to-severe symptoms and 42% for gastrointestinal symptoms. This suggests that 40% is a viable threshold for establishing a possible ''safety subgroup,'' with the greatest benefit from omalizumab. As shown in Fig 5, omalizumab-treated subjects whose baseline CD63 percentage was greater than 40% experienced far fewer symptoms than the corresponding placebo-treated subjects (P 5 .0004 for moderate-to-severe symptoms, P < .0001 for any symptoms other than oropharyngeal, and P 5 .0028 for gastrointestinal symptoms). Although there was some indication of an omalizumab advantage in the small cohort with baseline CD63 percentages of less than the 40% threshold, the magnitude of the treatment benefit appeared much less than that in the greater than 40% subgroup (Fig 5) . Table E1 in this article's Online Repository at www. jacionline.org predicts how success rates (defined as a reduction in moderate-to-severe symptoms, gastrointestinal symptoms, and any symptom other than oropharyngeal to <0.25%, <2%, and <5%, respectively) would change in the placebo group if those subjects who fell into the ''safety subgroup'' had been treated with omalizumab under the assumption that patients in this subgroup had the same success rate observed in the corresponding subgroup in the omalizumab arm.
When all study participants were evaluated as a single group, a strong positive association was noted between the frequency of moderate-to-severe symptoms during MOIT and CD63 percentage expression by using 10 mg/mL milk in the basophil assay measured at month 4 before MOIT was initiated (P 5 .0002, Fig  4) . This same pattern was significant in the omalizumab arm only at month 4 (P 5 .0490) and with other categories of symptoms, including gastrointestinal symptoms (P 5 .0004 overall and P 5 .0312 in the omalizumab arm at month 4) and any symptoms other than oropharyngeal (P < .0001 overall at month 4, Fig 4) . The observed reduction in CD63 percentages from baseline to month 4 in the omalizumab arm (particularly in the >40% subgroup) might be driving the large difference in the rate of symptoms during MOIT between the arms.
All other baseline measures of basophil reactivity also strongly associated with the frequency of symptoms (all 3 categories; see Fig E2, A-E, in this article's Online Repository at www.jacionline. org). Age at study entry was not associated with symptom frequency (see Fig E2, F) . Baseline milk IgE levels and milk IgE/total IgE ratio were not significantly associated with moderate-tosevere symptoms but overall showed moderate positive correlations with gastrointestinal symptoms (P 5 .0138 and P 5 .0309, respectively; see Fig E2, G) and any symptoms other than oropharyngeal (P 5.0209 and P 5.0282, respectively; Fig E2, G) . Baseline casein IgG 4 /casein IgE levels and b-lactoglobulin IgG 4 /blactoglobulin IgE ratios were overall not significantly associated with symptoms (see Fig E2, H) .
Relationship between baseline biomarkers and clinical outcome
Subjects whose baseline CD63 percentage at 10 mg/mL milk was greater than 40% were not more likely to achieve SU if they received omalizumab, despite the strong safety advantage in this subgroup (see Fig E3 in this article' s Online Repository at www. jacionline.org). However, a logistic regression model that allowed the effect of omalizumab on achieving SU to vary with the baseline ratio of CD63 percentage at 10 mg/mL milk over CD63 percentage to anti-IgE found a significant advantage in the omalizumab group starting at baseline ratios of 2.82 (Fig 6) . Among omalizumab-treated subjects whose ratio was greater than 2.82, 7 of 9 exhibited SU in the omalizumab group compared with 0 of 4 in the placebo group. Relationships of other baseline markers of basophil activation with clinical outcome are displayed in Fig E4, A-D, in this article's Online Repository at www.jacionline.org.
Furthermore, the baseline milk IgE/total IgE ratio was strongly associated with the SU outcome. Overall, subjects who achieved SU had significantly lower baseline milk IgE/total IgE ratios than those who did not achieve this end point (P 5 .0002, Fig 6) . This relationship was highly significant in the omalizumab arm (P 5 .0001, Fig 6) but did not reach significance in the placebo arm when analyzed separately (Fig 6) . Omalizumab-treated subjects whose ratio was low (less than about 0.1) generally achieved SU, which was not true for corresponding placebo-treated subjects. Baseline milk IgE level alone was also lower overall and the casein IgG 4 /IgE ratio was higher in subjects who passed the month 32 OFC (P 5 .0032 and .0052, respectively; see Fig E4 , E and F) and in the omalizumab arm only (P 5 .017 and .0083, respectively; see Fig E4, E and F) . Baseline milk IgE/total IgE ratio (Fig 6) , milk IgE level (see Fig E4, E) , casein IgG 4 /IgE ratio (see Fig E4, F) , and b-lactoglobulin IgG 4 /IgE ratio (see Fig E4,  G) were not significantly associated with the outcome of the month 28 desensitization challenge. Age of the subject at entry to the study was not associated with the likelihood of passing the month 28 or month 32 OFC (see Fig E4, H) .
Because there was some indication that the effect of omalizumab on SU can vary with both the baseline ratio of CD63 percentage at 10 mg/mL milk over CD63 percentage to anti-IgE and the milk IgE/total IgE ratio, we next explored whether a combination of these biomarkers would identify a potential subgroup of patients who might most benefit from omalizumab. We fit a logistic model that allowed the effect of omalizumab on achieving SU to vary with both of these variables. This exploratory analysis found a subgroup associated with a significant omalizumab group effect, but we focused on a broader subgroup in which the estimated treatment effect was positive but not necessarily significant, as indicated by the shaded region in Fig 7, A, showing CD63 percentage at 10 mg/mL milk/CD63 percentage to anti-IgE greater than 0.91 1 10.983 (milk IgE/total IgE), which splits the sample exactly in half (Fig 7, A) . Within this ''efficacy subgroup,'' 9 of 12 subjects in the omalizumab arm achieved SU versus 4 of 14 subject in the placebo arm (P 5 .0472; Fig 7,  B) . If the 14 placebo-treated subjects who fell into this efficacy subgroup had been treated with omalizumab, the predicted success rate for achieving SU in the full placebo cohort would have increased from approximately 33% to 57% (see Table  E1 ), assuming that the placebo-treated patients in this subgroup would have experienced exactly the same success rate as the corresponding subgroup in the omalizumab arm. Omalizumab-treated subjects also experienced a significant advantage with respect to the ordered clinical response (ie, where SU is the best outcome, desensitization is intermediate, and failed is worst; P 5 .0211). This same subgroup also showed a dramatic decrease in all categories of symptoms compared with placebo (P 5 .0025, .0041, and <.0001 for moderate-to-severe, gastrointestinal, and any symptoms other than oropharyngeal, respectively; Fig 7, C) . Omalizumab-treated subjects in the complementary subgroup (CD63 percentage at 10 mg/mL milk/CD63 percentage to antiIgE < 0.91 1 10.983 [milk IgE/total IgE]) did not have a higher rate of SU than placebo-treated subjects (Fig 7, B) . This subgroup still showed significantly reduced symptoms compared with placebo-treated subjects (P 5 .0049, .0410, and .0133 for moderate-to-severe, gastrointestinal, and any symptoms other than oropharyngeal, respectively; Fig 7, C) , although the extent of the reduction observed was not as great.
Relationship between concurrent biomarkers and clinical outcome
Overall, subjects who passed the month 28 desensitization challenge had significantly lower CD63 percentages at milk concentrations of 1 and 10 mg/mL and area under the curve (AUC) and higher casein IgG 4 /IgE and b-lactoglobulin IgG 4 /IgE ratios at month 28 compared with those in whom the desensitization challenge failed (P 5 .0019, .0007, .0036, .0304, and .0288, respectively; see Fig E5, A-C, G, and H, in this article's Online Repository at www.jacionline.org). This relationship was strongest in the omalizumab arm (P 5 .0067 for all 3 basophil biomarkers and P 5 .0191 for the casein IgG 4 /IgE ratio) and did not reach significance in the placebo arm when considered separately (see Fig E5, A-C) .
These same biomarkers measured at visit month 32 were also strongly associated with the outcome of the month 32 OFC. Overall, subjects who passed this OFC had a lower CD63 percentage at 1 and 10 mg/mL of milk and AUC and higher casein IgG 4 /IgE and b-lactoglobulin IgG 4 /IgE ratios compared with those who did not pass (P 5 .0114, .0369, .0239, .0018, and .0015, respectively; see Fig E5, A-C, G, and H) . No basophil biomarker measured at month 28 or 32 as a ratio over CD63 percentage to anti-IgE was significantly associated with the outcome of the month 28 or 32 OFCs, respectively (see Fig E5, D-F) .
DISCUSSION
Several immunotherapy approaches are currently under investigation for the treatment of food allergy, with OIT providing the greatest degree of desensitization and SU. However, the clinical benefits of OIT are limited by the frequent occurrence of adverse effects, including systemic reactions and intolerable gastrointestinal symptoms.
2,3 Recently, we reported that addition of omalizumab to a standard MOIT regimen could improve the safety of MOIT, although no benefit in enhancing desensitization or SU was detected. 4 In this study further post hoc analyses demonstrate that omalizumab exerts distinct effects on basophil activation beyond those induced by MOIT alone but did not enhance allergen-induced Treg cell development. Furthermore, we identified subgroups of patients based on their pretreatment basophil reactivity and/or allergen-specific/total IgE ratio who might be most likely to benefit from omalizumab in terms of reducing symptoms and achieving SU.
Several trials have previously demonstrated marked suppression of allergen-induced basophil responses after monotherapy with either OIT or omalizumab. 13, [18] [19] [20] [21] [22] We also observed decreased basophil CD63 expression at the month 4 visit (before initiation of MOIT) in subjects receiving omalizumab but not placebo and in both groups after the addition of MOIT. However, combined treatment with omalizumab and MOIT led to an even greater reduction in basophil activation than that achieved with MOIT alone, particularly at the highest concentrations of milk. In contrast, no change in basophil HR was observed in washed basophil suspensions isolated from the placebo group, and HR actually increased in the omalizumab group after treatment with IgE receptor cross-linking stimuli (milk and anti-IgE). The incongruent results between these experiments suggest that serum factors, likely milk-specific IgG levels, which increase during OIT, 4 might be largely responsible for the suppression in basophil reactivity observed in whole blood samples. No change in basophil HR to milk was reported in a previous MOIT study in which washed cell preparations were used. 23 The increase in HR to IgE cross-linking stimuli that we observed in washed cells from omalizumab-treated subjects is consistent with prior studies in which omalizumab was found to enhance markedly the sensitivity of basophils to degranulation. [10] [11] [12] Two competing factors have been found to influence changes in basophil reactivity after omalizumab therapy: (1) a decrease in allergen-specific IgE levels on the basophil surface and (2) an increase in the intrinsic sensitivity of basophils to IgE-mediated stimulation. [10] [11] [12] In this study a third variable, MOIT and the resulting increase in milkspecific IgG levels, 4 also likely influenced overall basophil responsiveness, leading to a net decrease in CD63 expression in whole blood samples at least early in the course of treatment.
Basophils from more than 80% of children with food allergy spontaneously release histamine, 24 and monotherapy with either omalizumab or OIT has been shown to suppress this phenomenon. 13, 23, 25 In addition, we observed a qualitative decrease in spontaneous HR with omalizumab (month 4 compared with baseline in the treatment group) and in both groups after the start of MOIT. The decrease in both milk-induced CD63 expression and spontaneous HR are consistent with an overall suppression of IgE-mediated basophil activation with OIT.
Despite the decreases in milk-induced basophil CD63 expression early in MOIT treatment in both the omalizumab and placebo groups, as previously reported, basophil reactivity returned to baseline after MOIT had been discontinued for 8 weeks (month 32) and in some subjects despite continued maintenance dosing (month 30). 4 Immunologic suppression during OIT has been shown to be transient, and these data suggest that the addition of omalizumab is not sufficient to prevent this reversal. 18 Interestingly, the degree of suppression in milk-induced CD63 expression at months 28 and 32 was strongly associated with the likelihood of passing an OFC at these visits, suggesting that inhibition of basophil reactivity might be central to the underlying mechanisms responsible for desensitization to milk.
Treg cells are a class of T cells that are thought to suppress allergic immune responses and promote tolerance to food antigens. Several prior studies have investigated the role of Treg cells in the development of desensitization to food allergens during OIT, with conflicting results. 18, 20, 26, 27 In this study we did not find an increase in the frequency of milk-specific Treg cells during MOIT, including in subjects who received omalizumab. These Not SU) . B, Number of omalizumab-or placebo-treated subjects whose baseline biomarker values were greater than (%CD63 Milk10/anti-IgE > 0.091110.98x IgE Ratio: Milk/Total) or less than (%CD63 Milk10/ anti-IgE < 0.091110.98x IgE Ratio: Milk/Total) the line of positive effect described in Fig 7, A, who achieved SU, were desensitized only (D), or failed (F). P values for a difference in SU (SU. p) and for a difference in ordinal outcomes (SU/D/F; ord. p) are presented. C, Percentage of MOIT doses that led to moderate-tosevere (Mod/Severe) symptoms, gastrointestinal (GI) symptoms, or any symptom excluding oropharyngeal symptoms (Symptoms excl. oral) over the course of MOIT in the 2 subsets of subjects described in Fig 7, B . P values are indicated in the graphs.
results are consistent with prior trials of omalizumab for asthma or milk allergy, in which no changes in Treg cell frequency were observed. 22, 28 These data suggest that the clinical benefits of omalizumab are unlikely to be mediated by Treg cell-dependent mechanisms or that the increase in Treg cell numbers is transient and not captured by the time points studied here.
OIT is often associated with a high rate of adverse reactions. Subjects who experienced the greatest frequency of reactions during MOIT also gained the least benefit clinically in terms of achieving desensitization or SU. These findings underscore the need to identify baseline biomarkers that can define this ''difficult-to-treat'' subset of patients who might benefit from omalizumab. Baseline allergen-specific/ total IgE ratios and basophil activation have been shown to be important indicators of clinical responses to omalizumab. 12, 29 Basophil responses have also been correlated recently with the severity and threshold of allergic reactions to peanut during OFCs and might be predictive of children who will outgrow their food allergy. 30, 31 In this study we detected a strong positive association between nearly all measures of baseline basophil reactivity and symptoms. Subjects whose baseline milk-induced CD63 expression was less than a threshold of 40% generally had infrequent symptoms (all categories) regardless of whether they received omalizumab, suggesting this group might not require adjunctive therapy. On the other hand, subjects whose basophils reacted at greater than this threshold were remarkably less likely to have symptoms if they received omalizumab. This likely reflects omalizumab's ability to effectively suppress basophil activation, as indicated by the marked reduction in CD63 expression between visits at month 4 (after starting omalizumab) and baseline, particularly in the greater than 40% subgroup.
A primary limitation of OIT for food allergy has been the lack of persistent clinical benefit once OIT is discontinued. However, baseline measures of basophil activation and serologic markers identified a subset of patients in whom omalizumab can enhance SU development. In this subgroup those who received omalizumab also experienced fewer symptoms (all categories) than their placebo-treated counterparts. Although widespread clinical use of omalizumab might not be possible given the significant costs, our data suggest there might be a subgroup of patients in whom this adjunctive therapy is warranted. The length of omalizumab therapy needed to confer improvements in safety, clinical outcomes, or both will require comparative trials in which the length of adjunctive treatment varies.
Our study has several important limitations. First, not all mechanistic assays were performed at all time points on all subjects, which might have limited our power. Second, we sought to identify subgroups of patients receiving MOIT who might benefit from combined therapy with omalizumab; however, the observed results are based on a small sample size, which precluded an independent validation. Third, we conducted many analyses, and therefore P values need to be interpreted cautiously. Nonetheless, this study demonstrates that omalizumab exerts distinct effects on basophil activation, and our analyses suggest that baseline biomarkers can predict a subset of patients in whom omalizumab might not only reduce the rate of adverse reactions but also possibly promote acquisition of SU. Confirmation of these findings in a larger prospective clinical trial is needed. d Baseline basophil CD63 expression was strongly associated with the occurrence of symptoms during OIT and might predict a subgroup of patients who will experience the most benefit from omalizumab in reducing adverse reactions.
d Baseline measures of basophil reactivity and the allergenspecific IgE/total IgE ratio might help identify subjects who are likely to benefit the most from adjunctive therapy with omalizumab during OIT in terms of both safety and likelihood of achieving SU.
METHODS
Basophil assays
Whole heparinized blood (0.25 mL per condition) was stimulated with anti-IgE (1 mg/mL; Bethyl Laboratories, Montgomery, Tex) or milk allergen (a 5-log concentration ranging from 0.001 to 10 mg/mL of aqueous extract of nonfat dried milk powder) in complete RPMI medium (Life Technologies, Grand Island, NY) with human recombinant IL-3 (R&D systems, Minneapolis, Minn) at 2 ng/mL for 30 minutes at 378C. In addition, control wells were mock stimulated with medium alone or IL-3 alone. The reaction was stopped by the addition of 2 mmol/L EDTA in PBS, and cells were surface stained with fluorescence-conjugated mAbs against CD203c (Beckman Coulter, Brea, Calif), CD63, CD123, CD69, CD3, CD14, CD19, CD41, and HLA-DR (BD Biosciences, Franklin Lakes, NJ). Red cells were then lysed, and white blood cells were fixed with BD FACS lysis buffer (BD Biosciences). Basophils were defined as CD123 At the Mount Sinai and Johns Hopkins sites, blood was collected in EDTA for histamine assays, diluted with normal saline, and subjected to 61% Percoll (Pharmacia Biotech, Piscataway, NJ) density centrifugation. The cell layer generated was aspirated and washed 4 times in piperazine-N,N9-bis(2-ethanesulfonic acid [PIPES])/albumin/glucose/EDTA and then again in PIPES/albumin/glucose (PAG). Cells were resuspended in PAG, divided equally, and cultured in a final volume of 50 mL in AIM V medium (Invitrogen Life Technologies, Carlsbad, Calif) containing the same panel of stimulants described above, except the culture medium did not contain IL-3. After a 45-minute incubation at 378C, 1 mL of PAG was added, and supernatants were frozen at 2208C until final HR assay. HR was measured in cell-free culture supernatants by using automated fluorometry. Percentage HR under each condition was calculated relative to total histamine content, which was determined by treating an identical number of cells with perchloric acid (1.6% final). Spontaneous HR was subtracted from values reporting HR in response to milk and anti-IgE.
Treg cell assays
PBMCs were labeled with 5 mmol/L carboxyfluorescein diacetate succinimidyl ester (Fisher Scientific, Pittsburg, Pa) and cultured with 50 mg/mL purified milk proteins (a, b, and k caseins; 50 mg/mL each) or medium alone in complete serum free AIM-V medium supplemented with IL-2 (10 ng/mL; R&D Systems) for 7 days. Cells were harvested; surface stained for CD3, CD4, CD25, and CD127 (BD Biosciences); and then fixed, permeabilized, and stained for FoxP3 (clone PCH101; eBioscience, San Diego, Calif), according to the manufacturer's protocol. Treg cells were defined as CD25 
Statistical analysis
We considered the following baseline biomarkers: percentage of CD63 1 cells at a dose of 1 and 10 mg/mL and the sum (AUC) of CD63 percentages after stimulation with the 5 dilutions of milk; these same 3 variables divided by CD63 percentage after anti-IgE stimulation; milk IgE levels; milkspecific IgE levels divided by total IgE levels; age at entry into the study; casein-specific IgG 4 levels divided by casein-specific IgE levels; and b-lactoglobulin IgG 4 levels divided by b-lactoglobulin IgE levels. One key variable, CD63 percentage at 10 mg/mL milk divided by CD63 percentage to anti-IgE, had 3 very significant outliers, with high values that were truncated to the value 5 for the purpose of graphics and parametric analyses so that these outliers would not have undue influence. Data on basophil biomarkers (CD63 percentage) were available at all time points on 52 of the 57 subjects enrolled, and serologic biomarkers were available on all 57 subjects throughout the study. A few analyses also evaluated postbaseline biomarker values. We considered the following outcomes: clinical (SU plus an ordinal clinical end point with SU as the best outcome, desensitized as intermediate, and neither as worst) and symptoms (any symptoms other than oropharyngeal, gastrointestinal symptoms, and moderate-to-severe symptoms). Moderate-to-severe reactions were defined as those that led to systemic hives and swelling, respiratory compromise, abdominal pain, repetitive vomiting, hypotension, or change in mental status. Although data on all subjects are represented, statistical analysis was limited to matched pairs between baseline and each of the time points studied (n 5 6, 10, and 10 in the omalizumab arm at months 4, 28, and 32, respectively; n 5 7, 8, and 6 in the placebo arm at months 4, 28, and 32, respectively). 
